Diagnoptics Technologies

Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader – a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.

AGE Reader https://www.diagnoptics.com/age-reader/

The AGE Reader is a non-invasive monitoring device that uses ultra-violet light to excite autofluorescence in human skin tissue. The autofluorescence is from the level of Advanced Glycation End products (AGEs). The measurement of AGEs provides an immediate cardiovascular risk prediction in 12 seconds. The AGE Reader has been designed for patient friendly diagnosis and because of this allows doctors to practice personalised care and prevent disease (progression). Additionally, the method is convenient, easy to use and extensively validated.